Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS.

Clin Cancer Res. 2019 Sep 15;25(18):5475-5484. doi: 10.1158/1078-0432.CCR-18-1881. Epub 2019 Jun 11.

PMID:
31186313
2.

Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.

Cruz-Correa M, Hylind LM, Marrero JH, Zahurak ML, Murray-Stewart T, Casero RA Jr, Montgomery EA, Iacobuzio-Donahue C, Brosens LA, Offerhaus GJ, Umar A, Rodriguez LM, Giardiello FM.

Gastroenterology. 2018 Sep;155(3):668-673. doi: 10.1053/j.gastro.2018.05.031. Epub 2018 May 23.

3.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2018 Jan;118(2):e2. doi: 10.1038/bjc.2017.418. Epub 2018 Jan 9. No abstract available.

4.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25. Erratum in: Br J Cancer. 2018 Jan 09;:.

5.

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.

Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA.

Clin Cancer Res. 2017 Aug 1;23(15):4027-4034. doi: 10.1158/1078-0432.CCR-17-0272. Epub 2017 Apr 4. Erratum in: Clin Cancer Res. 2018 Jan 15;24(2):500-501.

6.

Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.

Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2015 Mar;18(1):49-55. doi: 10.1038/pcan.2014.44. Epub 2014 Nov 11.

7.

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.

Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK.

Cancer Med. 2014 Oct;3(5):1322-35. doi: 10.1002/cam4.289. Epub 2014 Jul 3.

8.

Multidisciplinary service utilization pattern by advanced head and neck cancer patients: a single institution study.

Junn JC, Kim IA, Zahurak ML, Tan M, Fan KY, Lake ST, Zaboli D, Messing BP, Ulmer K, Harrer KB, Gold D, Ryniak KL, Zinreich ES, Tang M, Levine MA, Blanco RG, Saunders JR, Califano JA, Ha PK.

Int J Otolaryngol. 2012;2012:628578. doi: 10.1155/2012/628578. Epub 2012 Oct 18.

9.

Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients.

Zaboli D, Tan M, Gogineni H, Lake S, Fan K, Zahurak ML, Messing B, Ulmer K, Zinreich ES, Levine MA, Tang M, Pai SI, Blanco RG, Saunders JR, Best SR, Califano JA, Ha PK.

Int J Otolaryngol. 2012;2012:754191. doi: 10.1155/2012/754191. Epub 2012 Jun 21.

10.

Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.

Fan KY, Gogineni H, Zaboli D, Lake S, Zahurak ML, Best SR, Levine MA, Tang M, Zinreich ES, Saunders JR, Califano JA, Blanco RG, Pai SI, Messing B, Ha PK.

Ann Surg Oncol. 2012 Jun;19(6):1980-7. doi: 10.1245/s10434-012-2219-4.

11.

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.

Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA.

Cancer. 2012 Mar 15;118(6):1533-42. doi: 10.1002/cncr.26437.

12.

Racial disparities in ovarian cancer surgical care: a population-based analysis.

Bristow RE, Zahurak ML, Ibeanu OA.

Gynecol Oncol. 2011 May 1;121(2):364-8. doi: 10.1016/j.ygyno.2010.12.347. Epub 2011 Feb 1.

PMID:
21288564
13.

Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors.

Durr ML, Mydlarz WK, Shao C, Zahurak ML, Chuang AY, Hoque MO, Westra WH, Liegeois NJ, Califano JA, Sidransky D, Ha PK.

PLoS One. 2010 May 26;5(5):e10828. doi: 10.1371/journal.pone.0010828.

14.

Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes.

Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK.

Gynecol Oncol. 2009 Dec;115(3):334-8. doi: 10.1016/j.ygyno.2009.08.025. Epub 2009 Sep 18.

PMID:
19766295
15.

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA.

J Clin Oncol. 2009 Oct 20;27(30):4986-93. doi: 10.1200/JCO.2009.21.9410. Epub 2009 Aug 31.

16.

Surgical care of young women diagnosed with ovarian cancer: a population-based perspective.

Tanner EJ, Zahurak ML, Bristow RE, Díaz-Montes TP.

Gynecol Oncol. 2008 Nov;111(2):221-5. doi: 10.1016/j.ygyno.2008.07.047. Epub 2008 Sep 10.

PMID:
18786718
17.

Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.

Santillan A, Govan L, Zahurak ML, Diaz-Montes TP, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2008 Jun;109(3):388-93. doi: 10.1016/j.ygyno.2008.01.006. Epub 2008 Apr 10.

PMID:
18405946
18.

A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers.

Gerardi MA, Santillan A, Meisner B, Zahurak ML, Diaz Montes TP, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2008 Feb;108(2):282-6. Epub 2007 Nov 19.

PMID:
18023851
19.

Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study.

Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2007 Dec;107(3):495-9. Epub 2007 Sep 12.

PMID:
17854870
20.

Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer.

Díaz-Montes TP, Zahurak ML, Bristow RE.

Gynecol Oncol. 2007 Dec;107(3):464-8. Epub 2007 Aug 31.

PMID:
17765297
21.

Concentration of uterine cancer surgical care among the elderly: a population-based perspective.

Díaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2007 Dec;107(3):436-40. Epub 2007 Aug 31.

PMID:
17764726
23.

Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.

Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Shih IM, Bristow RE.

Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6.

PMID:
17504374
24.

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.

Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE.

Cancer. 2007 Feb 15;109(4):685-91.

25.

Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results.

Diaz-Montes TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL.

Gynecol Oncol. 2007 Feb;104(2):366-71. Epub 2006 Oct 16.

PMID:
17049972
26.

Impact of surgeon specialty on ovarian-conserving surgery in young females with an adnexal mass.

Bristow RE, Nugent AC, Zahurak ML, Khouzhami V, Fox HE.

J Adolesc Health. 2006 Sep;39(3):411-6. Epub 2006 Jul 10.

PMID:
16919804
27.

Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer.

Alphs HH, Zahurak ML, Bristow RE, Díaz-Montes TP.

Gynecol Oncol. 2006 Dec;103(3):1048-53. Epub 2006 Jul 27.

PMID:
16876237
28.

Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality.

Díaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Bristow RE.

Gynecol Oncol. 2006 Dec;103(3):1043-7. Epub 2006 Jul 28.

PMID:
16876234
29.

Salvage cytoreductive surgery for recurrent endometrial cancer.

Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK.

Gynecol Oncol. 2006 Oct;103(1):281-7. Epub 2006 May 2.

PMID:
16631236
30.

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.

Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE.

J Clin Oncol. 2005 Dec 20;23(36):9338-43.

PMID:
16361633
31.

Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.

Díaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE.

Gynecol Oncol. 2006 Jan;100(1):139-44. Epub 2005 Sep 22.

PMID:
16182348
32.

Surgical care of elderly women with ovarian cancer: a population-based perspective.

Díaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Gordon TA, Armstrong DK, Bristow RE.

Gynecol Oncol. 2005 Nov;99(2):352-7. Epub 2005 Aug 1.

PMID:
16055176
33.

Abdominal carcinomatosis in women with a history of breast cancer.

Garg R, Zahurak ML, Trimble EL, Armstrong DK, Bristow RE.

Gynecol Oncol. 2005 Oct;99(1):65-70.

PMID:
15979132
34.

Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms.

Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens L, Cameron JL, Yeo CJ, Offerhaus GJ, Hruban RH, Goggins M.

Cancer Biol Ther. 2005 May;4(5):596-601. Epub 2005 May 13.

PMID:
15908786
35.

Cancer of the uterine corpus among Hispanic women living in the United States: patterns of staging, diagnosis, and primary treatment.

Díaz-Montes TP, Alberg A, Zahurak ML, Trimble EL, Bristow RE.

Gynecol Oncol. 2005 Mar;96(3):753-9.

PMID:
15721422
36.

Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.

Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB.

Biol Blood Marrow Transplant. 2005 Feb;11(2):101-7.

37.

Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions.

Kim MM, Clinger JD, Masayesva BG, Ha PK, Zahurak ML, Westra WH, Califano JA.

Clin Cancer Res. 2004 Dec 15;10(24):8512-5.

38.

Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.

Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A.

Cancer. 2004 Oct 1;101(7):1609-15.

39.

Ovarian cancer surgery in Maryland: volume-based access to care.

Bristow RE, Zahurak ML, del Carmen MG, Gordon TA, Fox HE, Trimble EL, Montz FJ.

Gynecol Oncol. 2004 May;93(2):353-60.

PMID:
15099945
40.

Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.

Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M.

Clin Cancer Res. 2004 Apr 1;10(7):2386-92.

41.

FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.

Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ.

Int J Gynecol Cancer. 2003 Sep-Oct;13(5):664-72.

PMID:
14675352
42.

Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors.

Del Carmen MG, Smith Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE.

Cancer. 2003 Oct 15;98(8):1658-63.

43.

Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.

Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, Wahl RL, Montz FJ.

Gynecol Oncol. 2003 Sep;90(3):519-28.

PMID:
13678719
44.

Recurrent micropapillary serous ovarian carcinoma.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ.

Cancer. 2002 Aug 15;95(4):791-800.

45.

Micropapillary serous ovarian carcinoma: surgical management and clinical outcome.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ.

Gynecol Oncol. 2002 Aug;86(2):163-70.

PMID:
12144823
46.

Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.

Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH, Goggins M.

Cancer Res. 2002 Mar 15;62(6):1868-75.

47.

Risk factors for post-stem cell transplant sinusitis.

Thompson AM, Couch M, Zahurak ML, Johnson C, Vogelsang GB.

Bone Marrow Transplant. 2002 Feb;29(3):257-61.

48.

Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma.

Berdeja JG, Jones RJ, Zahurak ML, Piantadosi S, Abrams RA, Borowitz MJ, Vogelsang GB, Noga SJ, Ambinder RF, Flinn IW.

Biol Blood Marrow Transplant. 2001;7(10):561-7.

49.

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.

Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, Jones RJ.

J Clin Oncol. 2001 Dec 1;19(23):4314-21.

PMID:
11731514
50.

Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.

Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML, Hart J.

Hum Pathol. 2001 Apr;32(4):379-88.

PMID:
11331954

Supplemental Content

Loading ...
Support Center